176 results on '"Cuzzi, Gilda"'
Search Results
2. Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection
3. Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study
4. Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay
5. Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases
6. Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2
7. Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients
8. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases
9. Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies
10. Alternative biomarkers of tuberculosis infection in patients with immune-mediated inflammatory diseases
11. Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine
12. Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection
13. First description of agonist and antagonist IP-10 in urine of patients with active TB
14. Evaluation of IP-10 in Quantiferon-Plus as biomarker for the diagnosis of latent tuberculosis infection
15. Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
16. Use of several immunological markers to model the probability of active tuberculosis
17. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients
18. Characterization of the immune impairment of tuberculosis and COVID-19 coinfected patients
19. The Third Dose of BNT162b2 COVID-19 Vaccine Does Not “Boost” Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis
20. Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection
21. Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
22. Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy
23. Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave
24. Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies.
25. Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
26. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis
27. ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients
28. Mycobacterium tuberculosis Immune Response in Patients With Immune-Mediated Inflammatory Disease
29. PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease
30. In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy
31. Multicenter analysis of sputum microbiota in tuberculosis patients
32. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
33. Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection
34. Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases
35. IP-10 detection in urine is associated with lung diseases
36. Modulation of whole-blood IGRA response in patients with latent TB infection during treatment
37. Evaluation of IP-10 in IGRA for LTBI diagnosis
38. Accuracy of whole blood IGRA in TB subjects with rheumatic disease
39. Impact of antiretroviral and tuberculosis therapies on CD4 + and CD8 + HIV/M. tuberculosis-specific T-cell in co-infected subjects
40. Modulation of QuantiFERON-TB-Gold Plus response in patients with active tuberculosis and latent infection during treatment
41. Characterization of the HBHA response in TB patients with or without HIV infection
42. Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection
43. Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages
44. Characterization of the CD4 and CD8 T-cell response in the QuantiFERON-TB Gold Plus kit
45. First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus
46. Impact of ART on CD4+/CD8+T-cell-specific response to copathogens in HIV-TB patients
47. Comparison of the accuracy of QuantiFERON TB gold in tube vs QuantiFERON-TB plus
48. CD8-response associates with active tuberculosis and TB2-tube response in the QuantiFERON-TB-Plus kit
49. Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis
50. CD27 expression as a new tool to distinguish active tuberculosis from latent infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.